000			02249 a2200601 4500
005			20250513030837.0
264		0	_c19940601
008			199406s 0 0 eng d
022			_a0008-543X
024	7		_a10.1002/1097-0142(19940501)73:9<2408::aid-cncr2820730926>3.0.co;2-m _2doi
040			_aNLM _beng _cNLM
100	1		_aVelasquez, W S
245	0	0	_aIntermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis. _h[electronic resource]
260			_bCancer _cMay 1994
300			_a2408-16 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadministration & dosage
650	0	4	_aBleomycin _xadministration & dosage
650	0	4	_aCombined Modality Therapy
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDexamethasone _xadministration & dosage
650	0	4	_aDoxorubicin _xadministration & dosage
650	0	4	_aEtoposide _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aFollow-Up Studies
650	0	4	_aHumans
650	0	4	_aL-Lactate Dehydrogenase _xblood
650	0	4	_aLymphoma, Non-Hodgkin _xdrug therapy
650	0	4	_aMale
650	0	4	_aMethotrexate _xadministration & dosage
650	0	4	_aMiddle Aged
650	0	4	_aPrednisone _xadministration & dosage
650	0	4	_aPrognosis
650	0	4	_aRadiotherapy Dosage
650	0	4	_aRemission Induction
650	0	4	_aSurvival Rate
650	0	4	_aVincristine _xadministration & dosage
650	0	4	_abeta 2-Microglobulin _xanalysis
700	1		_aMcLaughlin, P
700	1		_aFuller, L M
700	1		_aAllen, P K
700	1		_aTucker, S L
700	1		_aSwan, F
700	1		_aRodriguez, M A
700	1		_aHagemeister, F B
700	1		_aCabanillas, F F
773	0		_tCancer _gvol. 73 _gno. 9 _gp. 2408-16
856	4	0	_uhttps://doi.org/10.1002/1097-0142(19940501)73:9<2408::aid-cncr2820730926>3.0.co;2-m _zAvailable from publisher's website
999			_c7512718 _d7512718